Concurrent with the obesity epidemic, the prevalence of nonalcoholic fatty liver disease (NAFLD) has risen dramatically, becoming the most prevalent liver disorder in Western nations.[133] At present, no FDA-approved medications exist for NAFLD treatment, with the primary recommendation being lifestyle modifications aimed at weight reduction, which is often challenging to achieve and sustain.[134] Consequently, innovative therapeutic advancements like GLP-1 RAs are crucial. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.